ADC3680 + montelukast

ADC3680 + montelukast is an investigational **combination therapy** studied for the treatment of asthma. ADC3680 is a small molecule drug, potentially targeting allergic inflammation, administered as an add-on to inhaled corticosteroids, and montelukast is a leukotriene receptor antagonist widely used for asthma and allergic rhinitis. This combination was evaluated for improved efficacy in patients with inadequately controlled asthma, with clinical trials assessing lung function and safety when the two agents are co-administered. Montelukast acts by blocking leukotriene D4 at cysteinyl leukotriene receptor type-1, reducing airway inflammation and bronchoconstriction[1][2][3][4]. ADC3680’s mechanism is less publicly established, but it is presumed to complement anti-inflammatory activity. The developer of ADC3680 is Pulmagen Therapeutics, and montelukast is primarily manufactured by Merck (as Singulair) with many generics available[1][2][4].

Brand names

Singulair

Other names

montelukast